Cardiff Oncology, Inc.
CRDF
Positions held
Your positionsCRDF isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $82.46M | Enterprise value | $48.40M | Trailing P/E | — | Forward P/E | -1.98 |
| PEG | — | Price / book | 2.74 | Beta | 1.42 | Dividend yield | 0.00% |
| Revenue growth | -14.1% | Earnings growth | — | Gross margin | 0.0% | Operating margin | -92.5% |
| Profit margin | 0.0% | ROE | -94.1% | ROA | -46.7% | Debt / equity | 0.02 |
| Current ratio | 3.30 | Free cash flow | -$24.30M | Analyst recommendation | none | Mean target | $5.81 |
| 52w high | $3.31 | 52w low | $0.76 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.1M | $0.0M | $0.2M | $0.1M | $0.1M | — |
| Op margin | -9245.2% | -31341.5% | -3221.0% | -9978.3% | -12212.4% | — |
| Net income | -$9.2M | -$12.3M | -$7.2M | -$11.3M | -$13.9M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$9.6M | -$12.8M | -$7.8M | -$12.0M | -$14.8M | — |
- Revenue +154% vs prior quarter ($0.1M vs $0.0M).
- Operating margin expanded to -9245.2%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.6M | $0.7M | $0.5M | $0.4M | — |
| Op margin | -8256.3% | -7123.1% | -9305.7% | -10337.3% | — |
| Net income | -$45.9M | -$45.4M | -$41.4M | -$38.7M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$49.0M | -$48.7M | -$45.4M | -$39.9M | — |
Headlines — positive tone
• [OK · fundamentals] Cardiff Oncology Shares Rise After Upgrade From HC Wainwright
News
2026-09-16 · 3 Clinical-Stage Cancer Stocks With Pristine Balance Sheets
2026-09-15 · Cardiff Oncology Shares Rise After Upgrade From HC Wainwright
2026-09-15 · HC Wainwright Upgrades Cardiff Oncology to Buy From Neutral, Price Target is $9
2026-09-14 · Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement
2026-09-02 · Cardiff Oncology to Participate in September 2026 Conferences
2026-08-17 · CRDF: Second Quarter Earnings
2026-08-12 · William Blair Downgrades Cardiff Oncology to Market Perform From Outperform
2026-08-11 · Cardiff Oncology: Q2 Earnings Snapshot
2026-08-11 · Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update
2026-07-16 · Cardiff Oncology Insider Bought Shares Worth $1,000,000, According to a Recent SEC Filing
2026-07-15 · Cardiff Oncology Announces $10 Million Registered Direct Offering to Strengthen Working Capital
2026-07-15 · Cardiff Oncology to Raise $10 Million in Share, Warrant Sale
Price (daily)
Full chart · RSI · MACD · patterns